The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

• On Tuesday, Sana Biotechnology released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. The company's stock surged around 162% over the past five days and has a 52-week high of $12.00.
• RSI Value: 73.4                                
• SANA Price Action: Shares of Sana Biotechnology closed at $4.30 on Wednesday.

• On Dec. 19, Mesoblast announced the U.S. Food and Drug Administration (FDA) approved Ryoncil. Ryoncil is the first FDA approved therapy for children aged 2 months and older with steroid-refractory acute graft versus host disease (SR-aGvHD).. The company's stock gained around 53% over the past month and has a 52-week high of $22.00.
• RSI Value: 77.8
• MESO Price Action: Shares of Mesoblast fell 4% to close at $17.18 on Wednesday.